InspireMD (NYSE American:NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that its novel CGuard Embolic Prevention System (EPS) has been granted regulatory approval by the Therapeutic Goods Administration (Part of the Australian Government’s Department of Health) for commercial sale …

InspireMD (NYSE American:NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that its novel CGuard Embolic Prevention System (EPS) has been granted regulatory approval by the Therapeutic Goods Administration (Part of the Australian Government’s Department of Health) for commercial sale and reimbursement in Australia. Launch will commence immediately in collaboration with InspireMD’s local distribution partner, Diverse Devices of Sydney.

As quoted in the press release:

“Regulatory approval of CGuard™ EPS in Australia represents an important step toward our goal of expanding commercial availability into new territories, and the Asia-Pacific region represents a significant opportunity for our Company,” said James Barry, PhD, Chief Executive Officer of InspireMD. “With 22 million residents, Australia ranks third behind only Japan and China in terms of total healthcare spending. More significantly, however, is that Australia’s Therapeutic Goods Administration sets a very high bar in terms of regulatory and reimbursement approval of new medical devices. We believe our approval reflects not only the agency’s recognition of CGuard’s differentiating features versus conventional carotid stents, but also the need for safer treatments for carotid artery disease. We are eager to begin offering this novel technology to patients in Australia imminently.”

Aidan McEvoy, Director of Diverse Devices Pty Ltd., commented, “At Diverse Devices, we strive to bring the latest technologies to health care professionals across Australia, and we are pleased to add CGuard™ EPS to our portfolio of the most innovative stent products available on the market today.”

Click here to read the full press release.

Featured
IDBS, a Danaher operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management platform. Extracting valuable insights from process and quality data across the biopharmaceutical lifecycle is a time consuming and error prone process, requiring laborious manual work and multiple steps. IDBS Polar replaces paper records, spreadsheets ...

IDBS, a Danaher (NYSE:DHR) operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management (BPLM) platform.

Extracting valuable insights from process and quality data across the biopharmaceutical lifecycle is a time consuming and error prone process, requiring laborious manual work and multiple steps.

read more Show less
Transformative AI System Enhances Colorectal Cancer Detection Capabilities  Medtronic Canada ULC, a subsidiary of Medtronic plc — the global leader in medical technology — announced it has received a Health Canada licence for the GI Genius™ intelligent endoscopy module. GI Genius is a computer-aided detection system that uses artificial intelligence to highlight regions of the colon suspected to have visual ...

Transformative AI System Enhances Colorectal Cancer Detection Capabilities

 Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) — the global leader in medical technology — announced it has received a Health Canada licence for the GI Genius™ intelligent endoscopy module. GI Genius is a computer-aided detection (CADe) system that uses artificial intelligence (AI) to highlight regions of the colon suspected to have visual characteristics consistent with different types of mucosal abnormalities.

read more Show less
Thermo Fisher Scientific Inc. the world leader in serving science, today confirmed that its polymerase chain reaction TaqPath COVID-19 Combo Kit *, and TaqPath COVID-19 CE-IVD RT-PCR Kit *, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results. The Omicron variant, which was designated a " variant of concern " by the World Health ...

- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit *, and TaqPath COVID-19 CE-IVD RT-PCR Kit *, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results.

The Omicron variant, which was designated a " variant of concern " by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone. The WHO has reported that preliminary evidence suggests an increased risk of transmission compared to other variants of concern. This designation and information are leading to renewed travel restrictions and research to examine the variant's impact on efficacy of existing vaccines and tests. The WHO and European Centers for Disease Control have both reported that using S-gene target failure (SGTF) of the PCR assays as a proxy for the variant helped to identify Omicron. Cases of the variant were first identified in South Africa and have now been reported in at least a dozen countries around the world.

read more Show less

MARKETS

Markets
TSX20783.72+319.12
TSXV907.83-10.09
DOW34703.41+681.37
S&P 5004588.04+75.00
NASD15419.70+165.65
ASX7235.90-20.10

COMMODITIES

Commodities
Gold1767.66-14.16
Silver22.39+0.03
Copper4.29+0.04
Palladium1780.46+29.46
Platinum942.00+6.00
Oil67.07+1.50
Heating Oil2.11+0.04
Natural Gas4.11-0.15